 The FDA has granted Fast Track designation to Vor Biopharmas NASDAQ: VOR VOR33, lead engineered hematopoietic stem cell eHSC therapeutic candidate for acute myeloid leukemia AML. VOR33 consists of CRISPR genome-edited hematopoietic stem and progenitor cells that have been engineered to lack CD33. 